Follow Us

The Latest

Promo Image

Once a Day Kaletra Gets Approved for Treatment Experienced, but With Caution

In April 2010, the FDA approved the once-a-day dosing of Kaletra (lopinavir + ritonavir) for adults who have taken HIV therapy before but with two or less lopinavir mutations. This new dose is not recommended for those with 3 or more of the following...

Promo Image

Kaletra and Gemfibrozil (Lopid): A Match Not Made in Lipid Heaven: A Blog Entry by Myles Helfand

Here's a heads-up for those of you with HIV and high cholesterol/triglycerides: Depending on which HIV meds you're taking, lipid-busting drugs may not work exactly the way they're supposed to.

The latest item to add to your "Oh Great, Another Thing ...

Promo Image

ABT-378/Ritonavir and Efavirenz for Salvage Therapy in Patients Multiply-Exposed to PIs

ABT-378/ritonavir and efavirenz for salvage therapy in patients multiply-exposed to PIs (TuPeB3196) Authored by N. Clumek, P.M. Girard, A. Telenti, J. Rockstroh, S. Becker, A. Lazzarin, S. Brun, E. Sun, X.U. Yi

Some of the most exciting data p...

Promo Image

Kaletra™ (ABT-378/r) Application for Accelerated Approval

On June 1 Abbott Laboratories announced that it had filed a New Drug Application with the U.S. FDA for accelerated approval of its new protease inhibitor, new brand name Kaletra (pronunciation Kuh Lee Truh) (generic name lopinavir/ritonavir, most wid...

Promo Image

Lopinavir: The Most Potent Protease Inhibitor

Unprecedented Anti-HIV Activity Efficacy in Treatment-naive Persons Efficacy in Treatment-experienced Persons Beyond Resistance Conclusion Selected Sources

In a season that will likely see few drug candidates appearing on the market, Abb...

Promo Image

ABT-378: A New Protease Inhibitor From Abbott

An oral presentation by Dr. Sham from Abbott laboratories (abstr #14) and a large series of posters (#206-213) presented the first look at ABT-378, a novel protease inhibitor. ABT-38 was designed to overcome some of the limitations of ritonavir, and ...